Jefferies Reiterates Buy Rating on Moderna (MRNA): 'New Cancer Vaccine Data at AACR in Head/Neck'
Tweet Send to a Friend
Jefferies analyst Michael Yee reiterated a Buy rating and $125.00 price target on Moderna (NASDAQ: MRNA)The analyst comments "New cancer ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
